You are here

dasatinib

Dasatinib

Treatment type:

  • Oral therapies
Code name: 
BMS-354825
Commercial name: 
Sprycel
Treatment line: 
  • First line
  • Second line
  • Third line
  • Fourth line
  • Fifth line
Generation: 
Second

Dasatinib is a highly potent dual Src/Abl inhibitor. It inhibits most mutations with the exception of the T315i mutation. The results of CCyR and MMR are similar to nilotinib. When this inhibitor was employed as first-line treatment, the responses were deeper, faster and superior to imatinib. The major side effects of this TKI inhibitor are thrombocytopenia, pleural effusion and more rarely, pulmonary complications. 

Status: 
England
Available in England and the devolved NHS administrations as a routine treatment for its licensed indications
Scotland
Available as a routine treatment for its licensed indications
Wales
Available as a routine treatment for its licensed indications
Northern Ireland
Available as a routine treatment for its licensed indications